MGRX
Mangoceuticals, Inc.
Medical - Healthcare Information Services
Market Cap$6M
5Y Perf.-97.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MGRX vs MNMD
Revenue, margins, valuation, and 5-year total return — side by side.
MNMD
Mind Medicine (MindMed) Inc.
Biotechnology
Market Cap$2.04B
5Y Perf.+496.5%
MGRX vs MNMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MGRX | MNMD |
|---|---|---|
| Industry | Medical - Healthcare Information Services | Biotechnology |
| Market Cap | $6M | $2.04B |
| Revenue (TTM) | $467K | $0.00 |
| Net Income (TTM) | $-20M | $-184M |
| Gross Margin | 60.6% | — |
| Operating Margin | -41.4% | — |
| Total Debt | $215K | $0.00 |
| Cash & Equiv. | $59K | $258M |
MGRX vs MNMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MGRX
MNMD
| Stock | Mar 23 | May 26 | Return |
|---|---|---|---|
| Mangoceuticals, Inc. (MGRX) | 100 | 2.1 | -97.9% |
| Mind Medicine (Mind… (MNMD) | 100 | 596.5 | +496.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MGRX vs MNMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MGRX leads in 3 of 5 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Mind Medicine (MindMed) Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
MGRX
Mangoceuticals, Inc.
The Income Pick
MGRX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.90, yield 100.0%
- Rev growth -15.8%, EPS growth 48.7%
- Lower volatility, beta 0.90, Low D/E 1.5%, current ratio 0.05x
Best for: income & stability and growth exposure
MNMD
Mind Medicine (MindMed) Inc.
The Long-Run Compounder
MNMD is the clearest fit if your priority is long-term compounding.
- 5.1% 10Y total return vs MGRX's -99.4%
- +227.9% vs MGRX's -80.3%
- -41.8% ROA vs MGRX's -106.4%, ROIC -389.5% vs -83.8%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MGRX | -15.8% revenue growth vs MNMD's -64.9% |
| Stability / Safety | MGRX | Beta 0.90 vs MNMD's 1.68 |
| Dividends | MGRX | 100.0% yield; 1-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | MNMD | +227.9% vs MGRX's -80.3% |
| Efficiency (ROA) | MNMD | -41.8% ROA vs MGRX's -106.4%, ROIC -389.5% vs -83.8% |
MGRX vs MNMD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMNMDLAGGINGMGRX
MGRXMangoceuticals, Inc.
1leads
MNMDMind Medicine (MindMe…
2leads
6 Total Categories
CATEGORYLEADERvs MGRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MGRX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MNMD6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
MNMD6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MGRX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
MGRX and MNMD operate at a comparable scale, with $466,908 and $0 in trailing revenue.
| Metric | MGRXMangoceuticals, I… | MNMDMind Medicine (Mi… |
|---|---|---|
| RevenueTrailing 12 months | $466,908 | $0 |
| EBITDAEarnings before interest/tax | -$17M | -$156M |
| Net IncomeAfter-tax profit | -$20M | -$184M |
| Free Cash FlowCash after capex | -$6M | -$161M |
| Gross MarginGross profit ÷ Revenue | +60.6% | — |
| Operating MarginEBIT ÷ Revenue | -41.4% | — |
| Net MarginNet income ÷ Revenue | -42.5% | — |
| FCF MarginFCF ÷ Revenue | -12.6% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -36.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +30.5% | -22.0% |
MGRX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — MGRX and MNMD each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | MGRXMangoceuticals, I… | MNMDMind Medicine (Mi… |
|---|---|---|
| Market CapShares × price | $6M | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $6M | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.08x | -10.04x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 9.28x | — |
| Price / BookPrice ÷ Book value/share | 0.05x | 5.56x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — MGRX and MNMD each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MNMD leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
MNMD delivers a -55.3% return on equity — every $100 of shareholder capital generates $-55 in annual profit, vs $-115 for MGRX. On the Piotroski fundamental quality scale (0–9), MGRX scores 4/9 vs MNMD's 3/9, reflecting mixed financial health.
| Metric | MGRXMangoceuticals, I… | MNMDMind Medicine (Mi… |
|---|---|---|
| ROE (TTM)Return on equity | -114.6% | -55.3% |
| ROA (TTM)Return on assets | -106.4% | -41.8% |
| ROICReturn on invested capital | -83.8% | -3.9% |
| ROCEReturn on capital employed | -107.8% | -52.2% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.02x | — |
| Net DebtTotal debt minus cash | $156,309 | -$258M |
| Cash & Equiv.Liquid assets | $58,653 | $258M |
| Total DebtShort + long-term debt | $214,962 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -581.90x | -14.63x |
MNMD leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
MNMD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNMD five years ago would be worth $4,045 today (with dividends reinvested), compared to $59 for MGRX. Over the past 12 months, MNMD leads with a +227.9% total return vs MGRX's -80.3%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs MGRX's -73.1% — a key indicator of consistent wealth creation.
| Metric | MGRXMangoceuticals, I… | MNMDMind Medicine (Mi… |
|---|---|---|
| YTD ReturnYear-to-date | -58.9% | +51.7% |
| 1-Year ReturnPast 12 months | -80.3% | +227.9% |
| 3-Year ReturnCumulative with dividends | -98.0% | +510.3% |
| 5-Year ReturnCumulative with dividends | -99.4% | -59.6% |
| 10-Year ReturnCumulative with dividends | -99.4% | +512.1% |
| CAGR (3Y)Annualised 3-year return | -73.1% | +82.7% |
MNMD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MGRX and MNMD each lead in 1 of 2 comparable metrics.
Risk & Volatility
MGRX is the less volatile stock with a 0.90 beta — it tends to amplify market swings less than MNMD's 1.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNMD currently trades 98.1% from its 52-week high vs MGRX's 12.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MGRXMangoceuticals, I… | MNMDMind Medicine (Mi… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.90x | 1.68x |
| 52-Week HighHighest price in past year | $2.75 | $21.09 |
| 52-Week LowLowest price in past year | $0.27 | $6.03 |
| % of 52W HighCurrent price vs 52-week peak | +12.8% | +98.1% |
| RSI (14)Momentum oscillator 0–100 | 42.0 | 64.9 |
| Avg Volume (50D)Average daily shares traded | 7.4M | 806K |
Evenly matched — MGRX and MNMD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
MGRX is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.
| Metric | MGRXMangoceuticals, I… | MNMDMind Medicine (Mi… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $20.00 |
| # AnalystsCovering analysts | — | 1 |
| Dividend YieldAnnual dividend ÷ price | +100.0% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $0.41 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MNMD leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). MGRX leads in 1 (Income & Cash Flow). 2 tied.
Best OverallMind Medicine (MindMed) Inc. (MNMD)Leads 2 of 6 categories
Loading custom metrics...
MGRX vs MNMD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MGRX or MNMD a better buy right now?
Analysts rate Mind Medicine (MindMed) Inc.
(MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MGRX or MNMD?
Over the past 5 years, Mind Medicine (MindMed) Inc.
(MNMD) delivered a total return of -59. 6%, compared to -99. 4% for Mangoceuticals, Inc. (MGRX). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus MGRX's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MGRX or MNMD?
By beta (market sensitivity over 5 years), Mangoceuticals, Inc.
(MGRX) is the lower-risk stock at 0. 90β versus Mind Medicine (MindMed) Inc. 's 1. 68β — meaning MNMD is approximately 86% more volatile than MGRX relative to the S&P 500.
04Which is growing faster — MGRX or MNMD?
On earnings-per-share growth, the picture is similar: Mangoceuticals, Inc.
grew EPS 48. 7% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MGRX or MNMD?
Mind Medicine (MindMed) Inc.
(MNMD) is the more profitable company, earning 0. 0% net margin versus -1413. 6% for Mangoceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNMD leads at 0. 0% versus -1294. 4% for MGRX. At the gross margin level — before operating expenses — MGRX leads at 61. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MGRX or MNMD?
In this comparison, MGRX (100.
0% yield) pays a dividend. MNMD does not pay a meaningful dividend and should not be held primarily for income.
07Is MGRX or MNMD better for a retirement portfolio?
For long-horizon retirement investors, Mangoceuticals, Inc.
(MGRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), 100. 0% yield). Mind Medicine (MindMed) Inc. (MNMD) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MGRX: -99. 4%, MNMD: +512. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MGRX and MNMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MGRX is a small-cap income-oriented stock; MNMD is a small-cap quality compounder stock. MGRX pays a dividend while MNMD does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.